# Combinent BioMedical Systems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/combinent-biomedical-systems

- Industry: Healthcare
- Headquarters: Lexington, US
- Website: www.combinentbiomedical.com
- Total disclosed funding: $3M
- Latest round: Series A (Apr 30, 2007)
- Investors on record: 3

## About

Combinent BioMedical Systems is a medical technology company focused on developing advanced biomedical solutions that enhance patient outcomes. Their innovative products improve diagnostics, monitoring, and therapeutic delivery across healthcare settings.Combinent BioMedical Systems specializes in creating innovative biomedical devices designed to improve patient care. The company is headquartered in Lexington, US. It has raised USD 0.6 mn in funding from undisclosed investors as of October 2012. The founder's details are not available, but the company has engaged in 6 total deals since inception.Combinent Biomedical specializes in innovative medical technologies aimed at enhancing patient outcomes in various healthcare settings. The company focuses on developing advanced biomedical devices and solutions that address critical needs in areas such as diagnostics, patient monitoring, and therapeutic delivery. Their core product offerings include state-of-the-art diagnostic equipment that integrates seamlessly with existing healthcare infrastructures, allowing for efficient data collection and analysis. These products are designed to be user-friendly for healthcare professionals and to improve patient care by providing accurate and timely information. Combinent Biomedical markets its products primarily to hospitals, clinics, and healthcare providers in North America and Europe, enabling a broad range of end users, including physicians, nurses, and patients.The revenue model of Combinent Biomedical is structured around direct sales and partnerships within the healthcare sector. The company engages in direct-to-consumer transactions and collaborates with healthcare facilities, offering tailored solutions to meet their specific needs. Revenue is generated through the sale of flagship products, which include proprietary diagnostic and monitoring devices. In addition to product sales, the company may also benefit from ongoing service contracts and support agreements with its clients, ensuring continuous engagement and support for their technologies. This transactional framework enables Combinent Biomedical to build lasting relationships with its customers while fostering a steady revenue stream from its innovative product offerings.In October 2012, Combinent BioMedical Systems received USD 0.6 mn in funding to enhance its operations. The company is focusing on expanding its product line with new advanced diagnostic tools set to launch in the next year. Additionally, it plans to enter international markets, specifically targeting Europe and Asia by the end of 2023. The recent funding will be utilized to support the development of these new products and facilitate its market expansion efforts.

## Funding rounds

- Series A, Apr 30, 2007, $3M — VIMAC Ventures, Commons Capital, Cytyc Development Company

## Investors

- VIMAC Ventures (https://capitalatlas.ai/funds/vimac-ventures) — Series A
- Commons Capital (https://capitalatlas.ai/funds/commons-capital) — Series A
- Cytyc Development Company — Series A